{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:03:10Z","timestamp":1761238990166,"version":"3.40.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The concept of standard of care (SoC) treatment is commonly utilized in clinical trials. However, in a setting of an emergent disease, such as COVID-19, where there is no established effective treatment, it is unclear what the investigators considered as the SoC in early clinical trials. The aim of this study was to analyze and classify SoC reported in randomized controlled trial (RCT) registrations and RCTs published in scholarly journals and on preprint servers about treatment interventions for COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross-sectional study. We included RCTs registered in a trial registry, and\/or published in a scholarly journal, and\/or published on preprint servers medRxiv and bioRxiv (any phase; any recruitment status; any language) that aim to compare treatment interventions related to COVID-19 and SoC, available from January 1, 2020, to October 8, 2020. Studies using \u201estandard\u201c treatment were eligible for inclusion if they reported they used standard, usual, conventional, or routine treatment. When we found such multiple reports of an RCT, we treated those multiple sources as one unit of analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 737 unique trials included in the analysis, 152 (21%) reported that SoC was proposed by the institutional or national authority. There were 129 (18%) trials that reported component(s) of SoC; the remaining trials simply reported that they used SoC, with no further detail. Among those 129 trials, the number of components of SoC ranged from 1 to 10. The most commonly used groups of interventions in the SoC were antiparasitics (62% of the trials), antivirals (57%), antibiotics (31%), oxygen (17%), antithrombotics\/anticoagulants (14%), vitamins (13%), immunomodulatory agents (13%), corticosteroids (12%), analgesics\/antipyretics (12%). Various combinations of those interventions were used in the SoC, with up to 7 different types of interventions combined. Posology, timing, and method of administration were frequently not reported for SoC components.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Most RCTs (82%) about treatment for COVID-19 that were registered or published in the first 9 months of the pandemic did not describe the \u201cstandard of care\u201d they used. Many of those interventions have, by now, been shown as ineffective or even detrimental.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-022-01646-1","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:06:00Z","timestamp":1655471160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Standard of care for COVID-19 in randomized clinical trials registered in trial registries and published in preprint servers and scholarly journals: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Mahir","family":"Fidahic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Nujic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Civljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Runjic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Markotic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Vidak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-6061","authenticated-orcid":false,"given":"Livia","family":"Puljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"1","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12874-020-01047-2","volume":"20","author":"M Fidahic","year":"2020","unstructured":"Fidahic M, Nujic D, Runjic R, Civljak M, Markotic F, Lovric Makaric Z, et al. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19. BMC Med Res Methodol. 2020;20(1):161.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"1646_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/15265160802654129","volume":"9","author":"R van der Graaf","year":"2009","unstructured":"van der Graaf R, van Delden JJ. What is the best standard for the standard of care in clinical research? Am J Bioethics: AJOB. 2009;9(3):35\u201343.","journal-title":"Am J Bioethics: AJOB"},{"issue":"3","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1377\/hlthaff.13.3.127","volume":"13","author":"SJ Reiser","year":"1994","unstructured":"Reiser SJ. Criteria for standard versus experimental therapy. Health Aff (Millwood). 1994;13(3):127\u201336.","journal-title":"Health Aff (Millwood)"},{"key":"1646_CR4","unstructured":"WHO International Clinical Trials Registry Platform (ICTRP). Available at: https:\/\/www.who.int\/ictrp\/en\/."},{"key":"1646_CR5","doi-asserted-by":"crossref","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3):269\u201371.","DOI":"10.1038\/s41422-020-0282-0"},{"key":"1646_CR6","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet."},{"issue":"1","key":"1646_CR7","first-page":"93","volume":"11","author":"P Eze","year":"2021","unstructured":"Eze P, Mezue KN, Nduka CU, Obianyo I, Egbuche O. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis. 2021;11(1):93\u2013107 eCollection 2021.","journal-title":"Am J Cardiovasc Dis"},{"key":"1646_CR8","first-page":"CD013587","volume":"2","author":"B Singh","year":"2021","unstructured":"Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2:CD013587.","journal-title":"Cochrane Database Syst Rev"},{"key":"1646_CR9","doi-asserted-by":"crossref","unstructured":"Kumar J, Jain S, Meena J, Yadav A. Efficacy and safety of hydroxychloroquine\/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. J Infect Chemother. 27(6):882\u20139.","DOI":"10.1016\/j.jiac.2021.02.021"},{"key":"1646_CR10","doi-asserted-by":"crossref","unstructured":"Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021;7(CD015017).","DOI":"10.1002\/14651858.CD015017"},{"issue":"6","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"e7967","DOI":"10.5867\/medwave2020067966","volume":"20","author":"F Verdugo-Paiva","year":"2020","unstructured":"Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Lopinavir-ritonavir for COVID-19: a living systematic review. Medwave. 2020;20(6):e7967. https:\/\/doi.org\/10.5867\/medwave2020067966.","journal-title":"Medwave"},{"key":"1646_CR12","doi-asserted-by":"crossref","unstructured":"Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir&#x2013;ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 396(10259):1345\u201352.","DOI":"10.1016\/S0140-6736(20)32013-4"},{"issue":"1","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/jbj202011005","volume":"44","author":"P Magro","year":"2021","unstructured":"Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E. Lopinavir\/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. Biom J. 2021;44(1):43\u201353. https:\/\/doi.org\/10.1016\/jbj202011005 Epub 2020 Nov 10.","journal-title":"Biom J"},{"issue":"1","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41182-021-00344-w","volume":"49","author":"YA Adebisi","year":"2021","unstructured":"Adebisi YA, Jimoh ND, Ogunkola IO, Uwizeyimana T, Olayemi AH, Ukor NA, et al. The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. Trop Med Health. 2021;49(1):51.","journal-title":"Trop Med Health"},{"issue":"1","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12941-021-00444-9","volume":"20","author":"A Yacouba","year":"2021","unstructured":"Yacouba A, Olowo-Okere A, Yunusa I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob. 2021;20(1):37.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"115094","DOI":"10.1016\/j.diagmicrobio.2020.115094","volume":"98","author":"E Ortiz-Prado","year":"2020","unstructured":"Ortiz-Prado E, Simba\u0102\u00b1a-Rivera K, G\u0102\u0142mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98(1):115094.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1646_CR17","doi-asserted-by":"publisher","first-page":"580585","DOI":"10.3389\/fpubh.2021.580585","volume":"9","author":"F Mansab","year":"2021","unstructured":"Mansab F, Donnelly H, Kussner A, Neil J, Bhatti S, Goyal DK. Oxygen and mortality in COVID-19 pneumonia: a comparative analysis of supplemental oxygen policies and health outcomes across 26 countries. Front Public Health. 2021;9:580585.","journal-title":"Front Public Health"},{"key":"1646_CR18","doi-asserted-by":"crossref","unstructured":"J-Fo L, Leclerc M, Chochois C, Monsallier J-M, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 18(7):1743\u20136.","DOI":"10.1111\/jth.14869"},{"issue":"7","key":"1646_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1055\/s-0040-1715456","volume":"46","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a Meta-analysis of literature studies. Semin Thromb Hemost. 2020;46(7):763\u201371. https:\/\/doi.org\/10.1055\/s-0040-1715456 Epub 2020 Sep 3.","journal-title":"Semin Thromb Hemost"},{"key":"1646_CR20","doi-asserted-by":"publisher","unstructured":"Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis. Int J Clin Pract. 2021:e14515. https:\/\/doi.org\/10.1111\/ijcp.14515.","DOI":"10.1111\/ijcp.14515"},{"issue":"4","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1213\/ANE0000000000005292","volume":"132","author":"JH Chow","year":"2021","unstructured":"Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021;132(4):930\u201341. https:\/\/doi.org\/10.1213\/ANE0000000000005292.","journal-title":"Anesth Analg"},{"key":"1646_CR22","unstructured":"Farid N, Rola N, Koch EAT, Nakhoul N. Active vitamin D supplementation and COVID-19 infections: review. Ir J Med Sci. 1971."},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/RMHPS291584","volume":"14","author":"H Yisak","year":"2021","unstructured":"Yisak H, Ewunetei A, Kefale B, Mamuye M, Teshome F, Ambaw B, et al. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review. Risk Manag Healthc Policy. 2021;14:31\u20138. https:\/\/doi.org\/10.2147\/RMHPS291584 eCollection 2021.","journal-title":"Risk Manag Healthc Policy"},{"key":"1646_CR24","doi-asserted-by":"crossref","unstructured":"Shakoor H, Feehan J, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, et al. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19? Maturitas. 143:1\u20139.","DOI":"10.1016\/j.maturitas.2020.08.003"},{"key":"1646_CR25","doi-asserted-by":"crossref","unstructured":"Zhou Y-F, Luo B-A, Qin L-L. The association between vitamin D deficiency and community-acquired pneumonia: A meta-analysis of observational studies. Medicine. 98(38):e17252.","DOI":"10.1097\/MD.0000000000017252"},{"key":"1646_CR26","unstructured":"Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. (5)."},{"key":"1646_CR27","doi-asserted-by":"publisher","unstructured":"Sahu AK, Mathew R, Bhat R, Malhotra C, Nayer J, Aggarwal P, et al. Steroids Use in Non-Oxygen requiring COVID-19 Patients: A Systematic Review and Meta-analysis. QJM. 2021:hcab212. https:\/\/doi.org\/10.1093\/qjmed\/hcab212.","DOI":"10.1093\/qjmed\/hcab212"},{"key":"1646_CR28","doi-asserted-by":"crossref","unstructured":"Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(CD014963).","DOI":"10.1002\/14651858.CD014963"},{"issue":"1","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12874-020-00972-6","volume":"20","author":"M Wolkewitz","year":"2020","unstructured":"Wolkewitz M, Puljak L. Methodological challenges of analysing COVID-19 data during the pandemic. BMC Med Res Methodol. 2020;20(1):81.","journal-title":"BMC Med Res Methodol"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-022-01646-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:08:06Z","timestamp":1655471286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-022-01646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1186\/s12874-022-01646-1","relation":{},"ISSN":["1471-2288"],"issn-type":[{"type":"electronic","value":"1471-2288"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"17 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a methodological study that analyzed trial registries and publications. Thus, no ethics approval was required for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Since December 15, 2021, Filipa Markotic has been employed by Teva Croatia, but she does not work in the field of interventions for COVID-19, and thus she has no conflicts of interest with the work presented in the manuscript.\u00a0Livia Puljak is a Senior Editorial Board member of the BMC Medical Research Methodology, but she was not involved in any way in handling of this manuscript. Other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}